Someone tested every promise on the multivitamin label. Not with one study — with nineteen meta-analyses and 5.5 million people. Six body systems. One scorecard.
Observational studies linked multivitamins to 12% lower heart disease across two million people. Controlled experiments found no effect. The difference was the people, not the pill.
There are six promises on most multivitamin labels. Your heart. Your immune system. Your brain. Your defense against cancer. Your eyes. And beneath all of them, the unspoken bet that the pill adds up to a longer life.
A research team at VU University Medical Center Amsterdam tested all six at once — not with a single experiment, but by pulling together nineteen meta-analyses that collectively covered more than 5.5 million people. Every body system the supplement industry builds its case on, measured with the most controlled study designs available.
One-third of American adults take a daily multivitamin [1]. The industry collects roughly $8 billion a year for that habit [1]. And until this review, nobody had scored the pill across every system it claims to support.
The score is in.
When researchers tested the daily multivitamin across every system it claims to support, the benefits they found belonged to populations the typical buyer isn’t part of.
- Controlled experiments covering millions of people found no benefit for cancer, heart disease, immunity, brain function, or mortality in healthy adults taking multivitamins.
- The one body system where multivitamins didn't score zero was eye health — and the result was doubled risk of macular degeneration progression.
- People who take multivitamins are measurably healthier, but the evidence shows the pill gets credit for their habits — they exercise more, eat better, and smoke less.
- Blood pressure dropped nearly 8 points in people who already had hypertension — but barely 1 point in healthy adults. Even the bright spots came with conditions.
- Every positive finding in this review belonged to a population with a specific condition — not the general gym-goer buying multivitamins for everyday health.
Six Promises, One Scorecard
Cancer. No effect. Across more than 1.7 million people, multivitamin use did not reduce breast cancer or prostate cancer. An 8% lower colorectal rate appeared in observational data — the only cancer result that moved in any direction, and limited to tracking studies.
Heart disease. No effect. Observational studies showed 12% fewer heart attacks among multivitamin users. Controlled experiments: 3% — indistinguishable from noise. The risk of dying from heart disease didn’t move.
Immunity. No effect in healthy adults. The only groups that saw fewer infections were hospitalized patients and the malnourished — populations the supplement aisle was never built for.
Brain function. No meaningful effect in the general population. One narrow slice of memory improved modestly. Delayed recall, verbal fluency, and broader cognition stayed flat.
Mortality. No effect. Across 21 controlled experiments and 91,074 people, taking a daily multivitamin was statistically indistinguishable from taking nothing at all.
Five systems. Five zeroes.
And then the sixth.
Across 13 controlled experiments and 85,321 people, multivitamin use didn’t score zero on eye health. It scored worse. The supplement was linked to a doubled risk of age-related macular degeneration progression. The one time the pill broke through the wall of zeroes, the direction was wrong.
The insurance policy that promised to cover everything covered nothing. And on one clause, it charged a penalty.
Why You Thought It Was Working
Here is the part that matters more than the scorecard.
Every time researchers simply observed who takes multivitamins and who doesn’t, the pill users looked healthier. Lower heart disease rates. Fewer hip fractures. Better colorectal numbers. The data, taken at face value, makes the pill look effective.
But every time they ran controlled experiments — gave some people the pill and others nothing, then compared results — the advantage vanished.
The explanation is not complicated. People who take multivitamins are healthier — but not because of the multivitamin.
They exercise more. They eat better. They smoke less. The pill sits beside those habits and quietly absorbs the credit.
The largest long-term study on this question tracked 390,124 adults for up to twenty-seven years and found no mortality benefit from daily multivitamin use [2]. But the people taking multivitamins in that study were, by every behavioral measure, healthier than those who didn’t.
You are probably demonstrating this right now. You work out, you pay attention to what you eat, you take the vitamin because it feels like part of the routine. And the vitamin gets credit for everything else you do.
You are the variable. Not the pill.
The stress reduction that multivitamins get credit for wasn't about the 'multi' part. Across eight controlled experiments, formulations loaded with high-dose B vitamins drove most of the improvement in stress, anxiety, and fatigue. Lower-dose broad-spectrum pills didn't match — meaning the pill's one psychological win may belong to a single ingredient group, not thirty.
What Harvard’s COSMOS Trial Actually Found
There is one legitimate defense of multivitamins, and it deserves its full hearing.
Harvard’s COSMOS trial — three separate experiments, 5,203 participants, adults aged sixty and older — found that daily multivitamin use improved memory and overall thinking ability. The effect was equivalent to slowing cognitive aging by roughly two years. The data held across all three. The finding was real.
And it belongs in the conversation — as context, not contradiction.
COSMOS applies to adults over sixty with heart disease risk factors. It covers one area of brain function in one age group. It does not extend to the thirty-year-old browsing the supplement aisle for “brain support.” It changes nothing about cancer, heart disease, immunity, or the eye finding.
The strongest counter-argument narrows the case instead of broadening it. The pill may have a role for one specific population and one specific outcome. For everyone else, the scorecard still reads zero.
Where the Bright Spots Sharpen the Point
The scorecard has real exceptions. Every one of them makes the conclusion more precise, not softer.
Blood pressure dropped meaningfully — nearly 8 points systolic — in people who already had hypertension. In adults with normal readings, the effect was barely 1 point. The pill moves the needle for a diagnosed condition. It does nothing for prevention.
Stress, anxiety, and fatigue improved in healthy adults across eight controlled experiments. Formulations heavy on B vitamins drove most of the effect. For people who are measurably stressed, the pill offers a small, real benefit.
Cognition improved in adults over sixty — the COSMOS data again, real but specific.
Every bright spot belongs to a population defined by a specific characteristic — hypertension, elevated stress, age-related cognitive decline. The person spending $30 a month on “total body wellness” typically has none of them. The pill works for conditions the casual gym-goer didn’t buy it for.
The bright spots don’t rescue the multivitamin. They sharpen the question of who it actually serves.
This review is not alone. A systematic review of 128 studies on mineral supplements in athletes found zero performance enhancement in well-nourished athletes. The International Society of Sports Nutrition’s 2026 position stand went further, noting that chronic high-dose antioxidant supplements may actually blunt training adaptations.
The choice isn’t between supplementing and not supplementing. It’s between a shotgun and a scalpel.
The Scalpel Principle
The researchers who assembled this scorecard drew a conclusion the supplement industry will not print on any label.
The case for broad multivitamin supplementation in healthy adults is not supported by the evidence. The case for targeted supplementation — finding what your body actually lacks and filling that specific gap — is.
Eighty-nine percent of Americans fall short on vitamin E from food alone. Forty-eight percent miss adequate magnesium [3]. The gaps are real. But spreading sub-therapeutic doses of thirty nutrients across one pill didn’t move outcomes on any system that matters to the person taking it.
The choice isn’t between supplementing and not supplementing. It’s between a shotgun and a scalpel. For specific nutrient gaps confirmed by bloodwork, the research on targeted supplementation tells a sharper story. What doesn’t work is betting on everything at once and hoping something lands.
If the shotgun fails, the natural question is what the scalpel should aim at — and whether individual nutrients like vitamin D and iron deliver what the broad pill could not.
This review tested the multivitamin on every system it claims to support — and every result in healthy adults came back at zero or worse.
What the data supports looks different from what the label promises. Specific nutrients, at specific doses, helped people with specific conditions. The researchers concluded that personalized strategies based on confirmed nutritional gaps carry more evidence than a daily broad pill.
The distinction isn't between supplementing and not supplementing. It's between knowing what's missing and guessing.
What other research found
What this means for you
This is the one age group where the scorecard looks different. Harvard's COSMOS trial found that daily multivitamin use improved memory and overall thinking ability in adults over sixty — an effect researchers described as equivalent to slowing cognitive aging by roughly two years.
The same review found that adults aged 65 to 74 had a 43% lower risk of nuclear cataracts in controlled experiments. Adults under 65 showed no cataract benefit at all.
Two positive signals in one population. Both from controlled experiments. Both specific to age-related conditions that the typical multivitamin buyer in their thirties isn't dealing with.
The blood pressure data splits cleanly by baseline status. In people who already had hypertension, multivitamin supplementation dropped systolic blood pressure by nearly 8 points. In people with chronic diseases, the reduction was about 6 points.
In people with normal readings? Less than 2 points — and the review found no evidence that multivitamins prevent hypertension from developing in the first place.
The researchers described this as a treatment effect for a diagnosed condition, not a prevention tool. The benefit exists — but it belongs to a population that already knows they have the condition.
This is the strongest positive territory in the entire review — and the one most disconnected from the casual supplement buyer.
Maternal multivitamin use was associated with a 33% lower risk of neural tube defects — serious conditions of the brain and spine — 23% fewer undersized births, and reduced rates of several childhood cancers including leukemia and brain tumors.
These findings come from observational data across 333,943 pregnancies. They don't prove causation, and folic acid's known role likely drives part of the effect. But the direction is consistent and the population is specific.
The evidence is especially clear for active people. A review of 128 studies covering 3,643 athletes found zero consistent evidence that mineral supplements improved performance in anyone eating well.
The International Society of Sports Nutrition's 2026 position stand went further: chronic high-dose antioxidant supplements may actually blunt your training adaptations. Your body uses the stress signals from a hard workout to get stronger — flooding it with antioxidants can dampen those signals.
The multivitamin isn't just doing nothing for your training. Depending on the dose, it may be quietly working against it.
Across eight controlled experiments, multivitamin supplementation reduced perceived stress, anxiety, and fatigue in healthy adults. The effects were small to moderate and showed up within 28 to 90 days.
What makes this finding sharper is the subgroup data: formulations heavy on B vitamins outperformed broader lower-dose pills. The benefit wasn't evenly distributed across the multivitamin — it tracked with one ingredient group.
One thing the data didn't find: any significant improvement in depression. The psychological benefit was real but specific — stress and anxiety, not mood disorders.
Before you change anything
This review covered adults aged 16 to 89 across 19 separate analyses, primarily from high-income countries. The narrative focuses on healthy adults — the person standing in the supplement aisle — because that's where the zeroes land hardest.
For populations with specific conditions — adults over 60, people with hypertension, pregnant women — the data tells a different story. Those findings are covered in the persona cards above.
Children and adolescents were excluded entirely. This review says nothing about pediatric multivitamin use outside of the maternal supplementation data, which examined what happened when mothers took multivitamins during pregnancy — not what happens when children take them directly.
No standard definition of 'multivitamin' exists across these studies. Some formulations contained 10 nutrients, others 30. Some had high-dose B vitamins, others spread doses thin across everything. Four of the included analyses explicitly flagged this as a problem — the label says 'multivitamin' but the contents vary wildly.
This was a rapid review, not a full systematic review. The researchers adopted a faster screening process, which means some relevant studies may have been missed. They registered their protocol and searched major databases, but the simplified approach creates a narrower net.
Several of the included analyses are over a decade old — some date to 2006 and 2007. Newer research may have been published since those analyses were completed.
The combined total of 5.5 million participants likely counts some of the same people more than once, since large groups in the US appear in multiple included analyses.
The mortality finding is rock-solid. When 91,074 people across 21 experiments show no mortality benefit, the statistical power to detect a real effect is enormous. If multivitamins helped people live longer, this data would have found it.
The heart disease finding is just as solid — over 2 million people in the combined data. The gap between what tracking studies showed and what experiments confirmed is itself a finding.
The eye disease harm signal deserves a nuance note: it comes from an analysis that compared treatments indirectly rather than head-to-head. The direction is real, but the confidence in exactly how large that risk is comes with more uncertainty than a direct experiment would allow.
The COVID data is underpowered — only 213 people across 3 trials. That group is too small to detect anything meaningful. The null result here carries far less weight than the mortality or cardiovascular nulls.
This review tested the broad pill. Separate research teams asked sharper questions — about individual nutrients at targeted doses in specific populations. What happens when iron-deficient female athletes get the right amount? What does vitamin D do for muscle strength when levels are genuinely low? Those answers don't inherit the multivitamin's zeroes. They stand on their own evidence.
What This Study Found
All findings from this paper, in plain language.
- Taking a daily multivitamin made no difference to lifespan across more than ninety thousand people tested in experiments.
- Multivitamin use showed no meaningful link to cancer risk — a small colorectal benefit in tracking studies was never tested in experiments.
- Heart disease rates looked lower among multivitamin users in tracking data, but experiments found no protective effect.
- Blood pressure dropped meaningfully in people with hypertension — nearly 8 points — but barely moved in healthy adults.
- Multivitamins did not reduce infections in healthy older adults — benefits appeared only in people who were hospitalized or not getting enough food.
- Across three small trials, multivitamins showed no effect on any COVID-19 outcome — but the group tested was too small to draw strong conclusions.
- Stress, anxiety, and fatigue improved in healthy adults taking multivitamins, with stronger effects from formulations heavy on B vitamins.
- Multivitamin use was linked to a doubled risk of macular degeneration progression — the only harm signal in the entire review.
- Adults over 65 taking multivitamins had a lower risk of cataracts in both tracking data and experiments. Adults under 65 showed no benefit.
- Multivitamin users had roughly half the risk of hip fractures in tracking data — but no experiment has confirmed this.
- Daily multivitamin use improved memory and cognition in adults over 60, equivalent to slowing cognitive aging by about two years.
- Children of mothers who took multivitamins during pregnancy had lower rates of leukemia and brain tumors — from tracking data only.
- Prenatal multivitamin use was linked to fewer neural tube defects and undersized births, though folic acid likely drove part of that effect.
- There is no standard definition of what counts as a multivitamin across studies — formulations varied so widely that comparisons are inherently messy.
- Benefits depended on who you are — varying by age, health status, and diet, supporting targeted approaches over one-size-fits-all recommendations.